



Nonclinical Safety Assessment

*A Guide to International
Pharmaceutical Regulations*

Editors

William J. Brock | Kenneth L. Hastings | Kathy M. McGown

 WILEY



Nonclinical Safety Assessment

A Guide to
International Pharmaceutical Regulations

Edited by

WILLIAM J. BROCK


Brock Scientific Consulting, Montgomery Village, USA

KENNETH L. HASTINGS

Sanofi, Bethesda, USA

KATHY M. McOWEN

FoxKiser, USA



 **WILEY**

A John Wiley & Sons, Ltd., Publication

This edition first published 2013
© 2013 John Wiley & Sons, Ltd

Registered office

John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, United Kingdom

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com.

The right of the author to be identified as the author of this work has been asserted in accordance with the Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. This work is sold with the understanding that the publisher is not engaged in rendering professional services. The advice and strategies contained herein may not be suitable for every situation. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of experimental reagents, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each chemical, piece of equipment, reagent, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

Library of Congress Cataloging-in-Publication Data

Nonclinical safety assessment : a guide to international pharmaceutical regulations / edited by William J. Brock, Kenneth L. Hastings and Kathy M. McGown.

p. ; cm.

Includes index.

ISBN 978-0-470-74591-5 (cloth)

1. Drug development—International cooperation. 2. Drugs—Toxicology—International cooperation. I. Brock, William J. II. Hastings, Kenneth L. III. McGown, Kathy M.

[DNLM: 1. Drug Evaluation, Preclinical—standards. 2. Drug Approval—methods. 3. Drug Toxicity—prevention & control. 4. International Cooperation. 5. Legislation, Drug. 6. Toxicity Tests—standards. QV 771]

RM301.25.N64 2013

615.1'901—dc23

2012037888

A catalogue record for this book is available from the British Library.

ISBN: 9780470745915

Set in 10/12pt, Times-Roman by Thomson Digital, Noida, India.

Printed and bound in Singapore by Markono Print Media Pte Ltd

Nonclinical Safety Assessment

List of Contributors

Shana Azri-Meehan, Forest Research Institute, Jersey City, USA

Matthew S. Bogdanffy, Boehringer Ingelheim Pharmaceuticals, Ridgefield, USA

William J. Brock, Brock Scientific Consulting, Montgomery Village, USA

Leigh Ann Burns-Naas, Gilead Sciences Inc., Foster City, USA

Cristiana Leslie Corrêa, Planitox, Campinas, Brazil

Luc M. De Schaepdrijver, Johnson & Johnson, Belgium

Jamie L. Doran, Intrinsic Health Sciences Inc., Mississauga, Canada

Christopher E. Ellis, CDER, Office of New Drugs, FDA, Silver Spring, USA

Fariza Feraoun, Laboratoires SERB, France

Malik Feraoun, Clinique Feraoun, France

Paul Donald Forbes, Toxarus Inc., Malvern, USA

Douglas Francis, DF Pre-clinical Services Pty Ltd., Hughes ACT, Australia

Lijie Fu, SNLB, China

Osamu Fueki, Pharmaceuticals and Medical Devices Agency, Japan

Hanan Ghantous, CDER, Office of New Drugs, FDA, Silver Spring, USA

Mark T. Goldberg, PlantForm Corporation and Karamella Consulting Inc., Guelph, Canada

Martin D. Green, CDER, Office of New Drugs, FDA, Silver Spring, USA

Melanie T. Hartsough, Biologics Consulting Group Inc., Derwood, USA

Kenneth L. Hastings, Sanofi, Bethesda, USA

Robert V. House, DynPort Vaccine Company LLC, Frederick, USA

Mark E. Hurtt, Pfizer, Groton, USA

Louise Latriano, ToxPharm Consulting LLC, Scotch Plains, USA

Kathy M. McGown, FoxKiser, USA

Kazuichi Nakamura, Shionogi & Co. Ltd., Global Regulatory Affairs Department, Japan

S. Natesan, Advinus Therapeutics Limited, India

Robert E. Osterberg, Osterberg Pharm-Tox Consulting, Rockville, USA

Marc J. Pallardy, School of Pharmacy and INSERM, University Paris-Sud, Chatenay, Malabry, France

Robert M. Parker, Huntingdon Life Sciences, East Millstone, USA

James A. Popp, Stratoxon, Lancaster, USA

Mark W. Powley, CDER, Office of New Drugs, FDA, Silver Spring, USA

K.S. Rao, Rao Toxicology Foundation (RTF), Sanjayanagar, India

Christopher P. Sambuco, Downingtown, USA

Giuliana Selmi, Planitox, Campinas, Brazil

Melissa S. Tassinari, CDER, Office of New Drugs, FDA, Silver Spring, USA

Jan-Willem van der Laan, FTBB, Medicines Evaluation Board, The Netherlands

Qingli Wang, Center for Drug Evaluation, SFDA, China

Adam Woolley, ForthTox Ltd., UK

Raymond G. York, RG York & Associates LLC, Manlius, USA

Flávio Ailton Duque Zambrone, Planitox, Campinas, Brazil

Preface

This book, *Nonclinical Safety Assessment: A Guide to International Pharmaceutical Regulations*, was conceived as an update to the Alder and Zbinden text on international nonclinical testing regulations. This out-of-print text was published in 1988 prior to ICH but, at the time, represented a reasonably complete description of the testing requirements for pharmaceuticals. Since that time, the pharmaceutical industry has seen the implementation of ICH, development of new guidance and guidelines from FDA and the EU (CHMP), a new regulatory process in China and other regions, implementation of FDAMA, and so on. It is hoped that this book provides a practical description of non-clinical drug development regulations in the major market regions although we do recognize that this is not a static but a dynamic process that continues to evolve almost on a daily or weekly basis. Although we attempted to capture the state-of-the-art in regulatory toxicology development, we also recognize that certain aspects will change even during the publishing process. Not all regions are covered in this edition of the book. However, with the evolution of ICH, it is likely that all pharmaceutical regions will adopt the ICH concept with minimal alternatives in the testing strategy.

Regardless, the objective of this text is to provide a guide for those involved in non-clinical drug development. As you will see from the layout of the book, the initial section discusses the legislative and regulations for different regions. This is followed by specific chapters on the conduct, interpretation and regulatory considerations of nonclinical studies. The final section of the book describes biotechnology-derived products, vaccines, and so on and the nonclinical challenges and solutions for the clinical development of these sometimes difficult therapeutics.

This text is intended for those actively involved in the clinical development of a pharmaceutical product, whether as a toxicologist, pharmacologist, clinician, project manager, and other functional responsibilities. The approaches and methodologies described throughout this book provide a useful and scientifically valid means to drug approval.

We hope you find this a very useful resource.

The Editors
December 2012

Contents

<i>List of Contributors</i>	xvii
<i>Preface</i>	xix
Part I International Regulations and Nonclinical Studies for Pharmaceuticals	1
1 Introduction	3
<i>Kathy M. McGown and William J. Brock</i>	
1.1 The Global Pharmaceutical Market	6
1.2 Looking to the Future	9
1.3 Legal and Regulatory Considerations in Drug Development	10
1.4 The Drug Development Process – General Considerations	12
References	15
2 ICH: History and Nonclinical Guidances	17
<i>Jan-Willem van der Laan and Kenneth L. Hastings</i>	
2.1 Introduction	17
2.2 Organization of the ICH	19
2.3 The ICH Process	20
2.4 Animal Welfare and Alternative Methods	22
2.5 ICH M3	23
2.6 New Initiatives and Topics	24
References	25
3 Food and Drug Administration: Nonclinical Program and Pharmaceutical Approval	27
<i>William J. Brock and Kenneth L. Hastings</i>	
3.1 Legislative Authority of the FDA	27
3.2 Nonclinical Drug Development and the FDA	31
3.3 Nonclinical Testing: General Conditions and Considerations	34
3.4 Toxicity Testing: Small Molecules and Traditional Pharmaceuticals	34
3.5 Toxicity Testing of Pharmaceuticals – The General Approach	35
3.6 First-in-Human Dosing: Results from Nonclinical Studies	37
References	38

4	Nonclinical Pharmaceutical Development in MERCOSUR and Brazil	41
	<i>Cristiana Leslie Corrêa, Giuliana Selmi, and Flávio Ailton Duque Zambrone</i>	
4.1	Introduction	41
4.2	MERCOSUR	41
4.3	Brazil	44
4.3.1	Brazilian Regulatory Aspects	44
4.3.2	Nonclinical Studies Required for Drug Registration	48
4.3.3	Comparison with Other Agencies and Harmonization Institutes	51
4.3.4	Regional Reality of Drug Registration – Final Comments	53
	References	54
5	Nonclinical Safety Assessment: Canada	57
	<i>Jamie L. Doran and Mark T. Goldberg</i>	
5.1	Introduction	57
5.2	Organization of Health Canada	58
5.2.1	Therapeutic Products Directorate	58
5.2.2	Biologics and Genetic Therapies Directorate	60
5.2.3	Natural Health Products Directorate	60
5.3	The Regulatory Framework for Drug Approval in Canada	60
5.3.1	The Food and Drugs Act	60
5.3.2	The Food and Drug Regulations	61
5.4	Nonclinical Assessment in Canada	64
5.4.1	Canada and the International Conference on Harmonization	64
5.4.2	Good Laboratory Practices in Canada	66
5.4.3	Case Studies and Summary Basis of Decision	67
5.5	Clinical Trial Applications	70
5.5.1	History and Regulations	70
5.5.2	Clinical Trial Application Overview	71
5.5.3	Pre-Submission Meetings and Consultations	71
5.5.4	CTA Content and Format	72
5.5.5	Nonclinical Aspects of the CTA/CTA-A Process	73
5.5.6	CTA-A Content and Format	73
5.5.7	CTA and CTA-A Review Process	73
5.6	Special Regulatory Considerations	74
5.6.1	Generic Drugs	74
5.6.2	Subsequent Entry Biologics in Canada	74
5.6.3	Orphan Drugs in Canada	77
	References	78
6	European Pharmaceutical Regulation – Nonclinical Testing Requirements	79
	<i>Adam Woolley and Jan Willem van der Laan</i>	
6.1	Introduction	79
6.1.1	Definitions	81
6.2	Regulation of Medicinal Products in the European Union	82

6.2.1	Overview	82
6.2.2	Role of the European Medicines Agency in the Regulation of Medicines	82
6.2.3	Scientific Structure of the EMA	83
6.2.4	Regulatory Process in the EU	85
6.3	Nonclinical Testing in the Support of Clinical Trials	86
6.3.1	Role of Individual Country Regulatory Agencies/Authorities	87
6.3.2	Risk Mitigation in Nonclinical Development of Medicinal Products	89
6.4	Overview	96
	References	96
7	South Africa	99
	<i>Fariza Feraoun and Malik Feraoun</i>	
7.1	Introduction	99
7.2	Country Information	100
7.2.1	Description	100
7.2.2	Economy	100
7.2.3	Country Organization	100
7.2.4	The Rainbow Nation	100
7.2.5	Health and Medicines	100
7.3	The Regulatory Aspects	101
7.3.1	The Registration of Medicines: Introduction and Scope	101
7.3.2	The Legal Framework	101
7.3.3	Role, Structure and Organization of the MCC	102
7.3.4	The Regulatory Procedures	103
7.3.5	The Registration Requirements for Preparation of the Application Package	104
7.3.6	The Registration Process: Several Steps of Review	108
7.4	The Nonclinical Safety Assessment	109
7.4.1	Introduction	109
7.4.2	Nonclinical Evaluation	109
7.4.3	Content of the Application for Safety Assessment	110
7.4.4	The Focus of the Nonclinical Evaluation	113
7.4.5	Pharmacology Testing	114
7.4.6	Toxicology Testing	114
7.5	Conclusion	114
7.5.1	Withdrawals	115
7.5.2	Consequences	115
7.5.3	New Safety Approach	115
8	Asia Pacific: China	117
	<i>Lijie Fu and Qingli Wang</i>	
8.1	Introduction	117
8.2	History of Drug Administration	118

8.3	The Provisions for Drug Registration	122
8.4	The SFDA	123
8.5	The SFDA Affiliated Organizations	123
	8.5.1 Center for Drug Evaluation (CDE)	123
	8.5.2 Center for Drug Re-evaluation (CDR)	124
	8.5.3 Certification Committee for Drugs (CCD)	124
	8.5.4 National Institutes for Food and Drug Control (NIFDC)	124
8.6	General Registration Procedures	125
8.7	Pharmaceutical Application	125
8.8	Import Drug Application	127
8.9	Testing Guidelines and Safety Evaluation	129
8.10	GLP Compliance in China	131
8.11	Animal Welfare Requirements	133
	References	133
9	Pharmaceutical Regulations for Nonclinical Safety Assessment in Japan	135
	<i>Kazuichi Nakamura and Osamu Fueki</i>	
9.1	History of Regulation for Nonclinical Safety Assessment in Japan	135
9.2	Approval Application of New Drugs in Japan	136
	9.2.1 Nonclinical Safety Studies Required for Drug Approval	136
9.3	Current Nonclinical Safety Guidelines Available in Japan	139
9.4	Current Trends of Conduct of Nonclinical Safety Evaluation in Japan	139
	9.4.1 Single-Dose Toxicity Studies	139
	9.4.2 Nonclinical Evaluation of the Potential for QT Interval Prolongation	139
	9.4.3 Carcinogenicity Studies	140
	9.4.4 Safety Evaluation of Drug Metabolites	140
	9.4.5 Phototoxicity Studies	140
	9.4.6 Skin Sensitization Studies	141
	9.4.7 Nonclinical Evaluation of Paediatric Drugs	141
	9.4.8 Antigenicity Studies	141
	9.4.9 Safety Evaluation of Chiral Pharmaceuticals	141
	9.4.10 Safety Evaluation of Impurities	141
	9.4.11 Other Studies	141
9.5	Safety Assessment of Unapproved Drugs	142
9.6	Necessity of 3Rs (Reduction/Refinement/Replacement) of Animal Studies	142
9.7	Attitude of Japanese Pharmaceutical Companies and the Regulatory Agency toward Nonclinical Safety Assessment	142
	References	143
10	Indian Regulatory Process for Nonclinical Drug Development	145
	<i>K.S. Rao and S. Natesan</i>	
10.1	Introduction	145
10.2	Drug Development	146
10.3	Quality Systems	147

10.4	Nonclinical Drug Development – Key Regulatory Requirements	148
10.5	Nonclinical Safety Assessment – Key Approval Requirements	149
10.6	Data Required for Clinical Study Approval	151
10.6.1	Animal Toxicity Studies as Mandated by Clinical Phases	152
10.6.2	Animal Toxicity Studies as Mandated by Proposed Route and Duration of Administration	152
10.7	Animal Toxicology	154
10.7.1	Systemic Toxicity Studies	155
10.7.2	Male Fertility Study	159
10.7.3	Female Reproduction and Developmental Toxicity Studies	159
10.7.4	Local Tolerance Studies	161
10.7.5	Allergenicity/Hypersensitivity	163
10.7.6	Genotoxicity	163
10.7.7	Carcinogenicity	165
10.8	Animal Pharmacology	166
10.8.1	General Principles	166
10.8.2	Specific Pharmacological Actions	166
10.8.3	General Pharmacological Actions – Essential Safety Pharmacology	166
10.8.4	Follow-up and Supplemental Safety Pharmacology Studies	167
10.8.5	Conditions under which Safety Pharmacology Studies are not Necessary	168
10.8.6	Timing of Safety Pharmacology Studies in Relation to Clinical Development	168
10.9	Safety Assessment Requirements: Indian Schedule Y and International Guidelines	168
10.10	Good Laboratory Practice Quality System in India	168
10.10.1	Indian National Compliance Monitoring Authority (NGCMA)	168
10.10.2	Mutual Acceptance of Data (MAD)	171
10.11	Safety Assessment Test Facilities in India	171
10.12	Investigational New Drug Application for Undertaking Clinical Trials	173
	References	173
11	Asia Pacific: Australia	175
	<i>Douglas Francis</i>	
11.1	Introduction	175
11.2	Australian Therapeutic Goods Administration (TGA)	176
11.2.1	Introduction	176
11.2.2	Legislative Backing	176
11.2.3	Information to be Supplied to the TGA to Support Inclusion of Therapeutic Goods in the ARTG	178
11.2.4	Evaluation Categories	180
11.2.5	Evaluation Fees and Timeframes	183
11.3	Clinical Trials in Australia	183
11.3.1	Introduction	183
11.3.2	Clinical Trial Schemes in Australia	183

11.3.3	Clinical Trial Process	184
11.3.4	CTN Scheme	185
11.3.5	CTX Scheme	186
11.3.6	Conducting Clinical Trials in Australia	187
11.4	Nonclinical Data to Support the Conduct of Clinical Trials in Australia and Marketing Application to the TGA	188
11.4.1	Introduction	188
11.4.2	Chemistry, Manufacturing and Controls	188
11.4.3	Nonclinical Pharmacology and Pharmacokinetics	189
11.4.4	Nonclinical Toxicology	190
11.4.5	Nonclinical Toxicology Studies	191
	References	195
Part II Toxicology Studies Supporting Clinical Development		197
12	Repeated-Dose Toxicity Studies in Nonclinical Drug Development	199
	<i>Shana Azri-Meehan and Louise Latriano</i>	
12.1	Introduction	199
12.2	General Considerations	200
12.2.1	Duration and Timing of Repeated-Dose Toxicology Studies	200
12.2.2	Anticancer Therapeutics	201
12.2.3	Assessment of Systemic Exposure	202
12.2.4	Qualification of Drug Substance and Product	203
12.2.5	Other Types of Applications/Submissions	203
12.3	Study Design Considerations	205
12.3.1	Selection of Animal Model	205
12.3.2	Size of Treatment Groups	206
12.3.3	Dose and Administration	208
12.3.4	Dose Selection	209
12.3.5	Test Article (Drug Substance) and Drug Formulation	210
12.4	Study Observations and Assessments	211
12.4.1	General	211
12.4.2	Clinical Observations	211
12.4.3	Food Consumption/Body Weight	213
12.4.4	Clinical Chemistry	213
12.4.5	Haematology	213
12.4.6	Urinalysis	213
12.4.7	Ophthalmologic Examinations	214
12.4.8	Electrocardiographic Examinations	214
12.4.9	Macroscopic Examination	214
12.4.10	Organ Weights	214
12.4.11	Histopathology	215
12.4.12	Additional Parameters	215
12.4.13	Medical Devices	216
	Acknowledgement	216
	References	216

13 Evaluation of Potential Carcinogenicity	219
<i>James A. Popp and Matthew S. Bogdanffy</i>	
13.1 Introduction	219
13.1.1 Short History of Carcinogenicity Testing	219
13.1.2 Objective of Carcinogenicity Testing	221
13.1.3 Overview of Regulatory Guidelines for Testing Carcinogenicity of Pharmaceuticals	222
13.2 Preparation for the Carcinogenicity Study	223
13.2.1 Timing in Relation to the Regulatory Submission	223
13.2.2 Evaluation of Available Toxicology Data	224
13.3 Elements of the Protocol/Study Plan	228
13.3.1 Species and Strain Selection	228
13.3.2 Route of Administration	229
13.3.3 Analysis of Drug and Dosage Formulation	230
13.3.4 Age of Animals	230
13.3.5 Group Size	230
13.3.6 Control Groups	231
13.3.7 Food Restriction	231
13.3.8 Routine Measurements	232
13.3.9 Dose Selection	232
13.3.10 Toxicokinetics	234
13.3.11 Clinical Pathology	234
13.3.12 Pathology	235
13.3.13 Satellite Groups for Mechanistic Studies	237
13.3.14 Review of Study Plan	237
13.3.15 Summary of Development of a Study Plan	241
13.4 Study Performance	241
13.4.1 Study Oversight During the In-Life Phase	241
13.4.2 Pathological Evaluation	242
13.5 Alternative Models to Evaluate Potential Carcinogenicity in Lieu of a 2-Year Mouse Study	244
13.6 Special Consideration for Carcinogenicity Evaluation of Biotherapeutics	247
13.7 Regulatory Implications of a Study Identifying an Animal Carcinogenic Response	248
13.8 Interpreting the Relevance of Positive Results for Human Safety	249
13.9 Communicating the Results in the Product Label	251
References	252
14 Genetic Toxicology	255
<i>Mark W. Powley</i>	
14.1 Background	255
14.2 Regulations Guiding Drug Development	256
14.2.1 Genetic Toxicology Assays	256

14.2.2	ICH Genetic Toxicology Battery	258
14.2.3	Positive Results and Follow-up	259
14.2.4	Timing	261
14.3	Genotoxic Impurities	261
14.3.1	<i>In Silico</i> Predictions	261
14.3.2	Empirical Testing	262
14.3.3	Safe Levels of Genotoxic Impurities	262
14.4	Regulatory Decision Making	263
	References	263
15	Developmental and Reproductive Toxicology	265
	<i>Robert M. Parker and Raymond G. York</i>	
15.1	Introduction	265
15.2	Standard Reproduction and Developmental Toxicity Study Designs	266
15.2.1	ICH 4.1.1 The Fertility and General Reproductive Performance Study (“Segment I”; Stages A to B)	266
15.2.2	ICH 4.1.2. The Prenatal and Postnatal Study (“Segment III”; Stages C to F)	268
15.2.3	ICH 4.1.3 The Developmental Toxicity or Embryotoxicity Study (“Segment II”; Stages C to D)	270
15.3	Timing of Preclinical Developmental and Reproductive Toxicity Studies	273
15.3.1	Based on Sex and Reproductive Potential	273
15.4	Based on Disease Indication	275
15.4.1	Anticancer Pharmaceuticals	275
15.4.2	Topical Microbicides Intended for Prevention of Viral Sexually Transmitted Diseases Including Human Immunodeficiency Virus (HIV)	277
15.4.3	Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives	277
15.4.4	Human Insulin Analogues	278
15.5	Based on Pharmaceutical Characteristic	279
15.5.1	Biotechnology-derived Products	279
15.5.2	Biosimilars	282
15.5.3	Vaccines	283
15.5.4	Botanical Drug Products	290
15.5.5	Contraceptive Steroids	290
15.5.6	Synthetic Sex Steroids Used in Food-Producing Animals	291
15.6	Other Reasons to Conduct Preclinical Reproductive and Developmental Toxicity Studies	291
15.6.1	Drug Combinations	291
15.6.2	Drug Metabolites	293
15.7	Excipients	293
15.8	Conclusion	293
	References	294

16 Juvenile Animal Toxicity Studies: Regulatory Expectations, Decision Strategies and Role in Paediatric Drug Development	297
<i>Melissa S. Tassinari, Luc M. De Schaepe-drijver, and Mark E. Hurtt</i>	
16.1 Introduction	297
16.2 Regulatory Environment	298
16.2.1 US Paediatric Laws: PREA and BPCA	298
16.2.2 EU Regulation	300
16.2.3 Guidances for Conduct of Juvenile Animal Studies	301
16.3 Relevance and Place in Drug Development	302
16.4 Strategies for Decision Making: When are Studies Needed and Appropriate?	304
16.4.1 Study Approach and Design	305
16.5 Case Studies: Application of Data Review and Decision Making	307
16.5.1 Adequacy of Existing Data to Support Clinical Development in Paediatric Populations	307
16.5.2 Nonclinical Juvenile Safety Testing to Support Clinical Development	308
16.5.3 Nonclinical Juvenile Safety Testing in Two Species	309
16.6 Summary	309
References	310
17 Immunotoxicology	313
<i>Leigh Ann Burns-Naas and Marc J. Pallardy</i>	
17.1 Introduction	313
17.2 Regulatory Expectations for the Immunotoxicology Evaluation of Pharmaceuticals	314
17.2.1 Adverse (Unintended) Immunomodulation – ICH S8, the Weight of Evidence Review, and Determination of “Cause for Concern”	314
17.2.2 Hypersensitivity	331
17.2.3 Autoimmunity	334
17.3 Special Considerations	335
17.3.1 Immunomodulatory Drugs	335
17.3.2 Biopharmaceuticals	335
17.3.3 Drugs in Pregnancy and Children – Developmental Immunotoxicology	338
17.4 Summary	342
References	342
18 Nonclinical Safety Assessment: Biotechnology-Derived Pharmaceuticals	347
<i>Christopher E. Ellis, Melanie T. Hartsough, Martin D. Green, and Hanan Ghantous</i>	
18.1 Introduction	347
18.2 Unique Characteristics of Biopharmaceuticals	348
18.3 Species Selection	349
18.3.1 Defining a Pharmacologically Relevant Species	350

18.3.2	Alternative Approaches	352
18.3.3	Utilizing Non-Pharmacologically Relevant Species	355
18.3.4	Additional Alternatives	355
18.4	Immunogenicity	356
18.5	Biological Activity/Pharmacodynamics	358
18.6	Pharmacokinetics/Toxicokinetics	359
18.7	Nonclinical Safety Assessment	362
18.7.1	General Principles	362
18.7.2	Study Design Considerations	363
18.7.3	Specialized Studies	368
18.8	Tissue Cross-Reactivity (TCR)	371
18.9	Clinical Starting Dose Selection for Biopharmaceuticals	373
18.10	Comparability	375
	References	377
19	International Safety Regulations for Vaccine Development	381
	<i>Robert V. House</i>	
19.1	Introduction	381
19.2	What “Toxicities” have been Attributed to Vaccination?	381
19.2.1	Immune System “Overload”	382
19.2.2	Increase in Allergy/Atopy	382
19.2.3	Autism	382
19.3	How Vaccines are (Slightly) Different from Other Biopharmaceuticals	383
19.4	Regulatory Framework for Assessing Safety of Vaccines	383
19.4.1	Quality Testing	384
19.4.2	Toxicology Testing	385
19.4.3	General Toxicology Study Design Considerations	386
19.5	Parameters Monitored	387
19.5.1	Safety Testing for Adjuvants	388
19.5.2	Reproductive Toxicology	388
19.5.3	Immunotoxicity	389
19.5.4	Genotoxicity	389
19.6	Clinical Safety Assessment of Vaccines	389
19.7	Summary	390
	References	390
20	Phototoxicity and Photocarcinogenicity	393
	<i>Robert E. Osterberg, Christopher P. Sambuco, and Paul Donald Forbes</i>	
20.1	History of Phototoxicity, Photocarcinogenicity and Photogenotoxicity Testing at the US Food and Drug Administration (FDA)	393
20.2	FDA Photosafety Testing Guidance	397
20.2.1	Status of In Vitro and In Vivo Phototoxicity Testing	400
20.3	Status of <i>In Vivo</i> Testing for Photocarcinogenesis	417
20.4	Photocarcinogenesis Study Designs	418